| Vol. 7.12 – 9 April, 2021 |
| |
|
|
| Genomic alterations in AT-rich interactive domain 1A (ARID1A) were analyzed in gastric adenocarcinoma. Mouse gastric epithelial cells from CK19-Cre-Arid1Afl/fl and wild-type mice were used to determine the activation of oncogenic genes due to loss of Arid1A. [Gut] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Mutationally activated KRAS in tumor cells reprograms macrophages to a tumor-associated macrophage-like phenotype via a combination effect of tumor-derived CSF2 and lactate. [Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators showed in rodent models that long-term consumption of a processed diet drives intestinal barrier permeability and an increased risk of chronic kidney disease. [Science Advances] |
|
|
|
| Scientists showed that microbial polyamines reinforce colonic epithelial proliferation and regulate macrophage differentiation. [Nature Communications] |
|
|
|
| In vitro and in vivo experiments showed that EIF3J-DT activated autophagy and induced drug resistance in gastric cancer cells by targeting ATG14. [Autophagy] |
|
|
|
| The authors investigated the effect of Src homology-2 domain-containing protein tyrosine phosphatase-2 on tumor cell-intrinsic STING pathway activity and DNA repair in colon cancer. [Cancer Research] |
|
|
|
| Researchers showed that the USP42 antagonized R‐spondin by protecting ZNRF3/RNF43 from ubiquitin‐dependent clearance. [EMBO Reports] |
|
|
|
| Homeobox C6 was validated to be overexpressed in right-sided colon cancer and associated with poor prognosis. [Cell Death & Disease] |
|
|
|
| Utidelone (UTD1) dramatically inhibited colorectal cancer cell proliferation in vitro. Immunofluorescence staining showed that UTD1 induced the formation of microtubule bundling and asters in RKO cells. [Cell Death & Disease] |
|
|
|
| Scientists discovered that LSD1 was important for goblet cell maturation and goblet-cell effector molecules such as RELMß. [PLoS Pathogens] |
|
|
|
| Researchers investigated the potential clinical utility of SLFN11 in the treatment of gastric cancer (GC). In GC cells and organoids, long-term treatment with oxaliplatin suppressed SLFN11 expression while imparting drug resistance. [British Journal of Cancer] |
|
|
|
| By using ex vivo 3D organoid cultures and molecular approaches scientists observed early responses to T3 involving the T3-metabolizing enzyme Dio1 and the transporter Mct10, accompanied by a complex response of stem cell- and progenitor-enriched genes. [Development] |
|
|
|
| Elevation of Cdc42 activity in young animals by genetic means causes premature ISC aging, whereas pharmacological suppression of elevated Cdc42 activity restores organoid formation potential in vitro. [iScience] |
|
|
|
|
| The authors highlight the pathways by which intestinal epithelial cells sense microbiota-derived signals and the necessity of these detection pathways in maintaining epithelial barrier integrity. [Genes & Immunity] |
|
|
|
|
| Daiichi Sankyo Company, Limited AstraZeneca announced that the first patient was dosed in DESTINY-CRC02, a global Phase II trial evaluating the efficacy and safety of ENHERTU® in patients with HER2 overexpressing locally advanced, unresectable or metastatic colorectal cancer with progression following treatment with standard of care chemotherapy. [Daiichi Sankyo Company] |
|
|
|
|
| January 12 – 14, 2022 Shanghai, China |
|
|
|
|
|
| Emory University – Atlanta, Georgia, United States |
|
|
|
| Technische Universität Dresden – Dresden, Germany |
|
|
|
|
| Weill Cornell Medicine – New York, New York, United States |
|
|
|
| Wellcome Trust Sanger Institute – Cambridge, England, United Kingdom |
|
|
|
|